The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baumann, H.
Right arrow Articles by Strassmann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baumann, H.
Right arrow Articles by Strassmann, G.

The Journal of Immunology, Vol 151, Issue 3 1456-1462, Copyright © 1993 by American Association of Immunologists

ARTICLES

Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6-type cytokines in rat hepatoma cells

H Baumann and G Strassmann
Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY 14263.

The cytokines, IL-1 beta, TNF-alpha, IL-6, IL-11, leukemia inhibitory factor, and ciliary neurotrophic factor, stimulate the expression of specific sets of acute phase plasma proteins in the rat hepatoma H-35 cell line. In this paper, the experimental drug suramin is shown to inhibit in a dose-dependent fashion the cell response to these cytokines, with the exception of TNF-alpha. The action of the IL-6-type cytokines is more sensitive to suramin inhibition that that of IL-1 beta. The effect of suramin is detectable within 30 min at the level of gene transcription and appears to be mediated by the impairment of receptor function and/or signal transduction, rather than by the inhibition of nucleic acid polymerases or DNA topoisomerase II. Similar analysis of human hepatoma HepG2 cells indicated a several-fold higher resistance to suramin and in inhibition that was less cytokine-specific than in H-35 cells. The data suggest that suramin has the potential not only to modulate the proliferation or differentiation of tumor cells as described previously, but also to affect a differentiated cell function. This broad pleiotropic action has to be taken into consideration when applying suramin as a therapeutic agent.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. S. Mummery and C. C. Rider
Characterization of the Heparin-Binding Properties of IL-6
J. Immunol., November 15, 2000; 165(10): 5671 - 5679.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Brosh, D. Sternberg, J. Honigwachs-Sha'anani, B.-C. Lee, Y. Shav-Tal, E. Tzehoval, L. M. Shulman, J. Toledo, Y. Hacham, P. Carmi, et al.
The Plasmacytoma Growth Inhibitor Restrictin-P Is an Antagonist of Interleukin 6 and Interleukin 11
J. Biol. Chem., December 8, 1995; 270(49): 29594 - 29600.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. K. Morella, C.-f. Lai, S. Kumaki, N. Kumaki, Y. Wang, E. M. Bluman, B. A. Witthuhn, J. N. Ihle, J. Giri, D. P. Gearing, et al.
The Action of Interleukin-2 Receptor Subunits Defines a New Type of Signaling Mechanism for Hematopoietin Receptors in Hepatic Cells and Fibroblasts
J. Biol. Chem., April 7, 1995; 270(14): 8298 - 8310.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.